Onureg: Clinical Trials

26 trials of Onureg, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 active not recruiting, 8 recruiting, 4 terminated, 3 completed. 26 Phase 2, 10 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 226Active not recruiting 8, Recruiting 8, Terminated 4, Completed 3, Withdrawn 2, Not yet recruiting 1
Phase 110Recruiting 4, Terminated 3, Active not recruiting 2, Completed 1
Phase 31Active not recruiting 1

Follow Onureg: new trials by email Literature Review of Onureg trials Research Report on Onureg

Trials (filtered) newest first · largest first

All 26 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML
Azacitidine, APG1252 - AML
Phase 1 / Phase 2RecruitingM.D. Anderson Cancer Center522026-05-222026-10-05
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Tagraxofusp, Azacitidine (AZA), Venetoclax - Acute Myeloid Leukaemia (AML), Leukemia
Phase 1 / Phase 2RecruitingJacqueline Garcia, MD312026-02-022026-02-05
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment
Cytarabine, Venetoclax, CPX-351 - Leukemia, Myeloid, Acute
Phase 2Not yet recruitingEastern Cooperative Oncology Group1842024-10-232024-07-03
Cladribine Venetoclax in Monocytic AML
Cladribine, Venetoclax, Azacitidine - Acute Myeloid Leukemia
Phase 2Active not recruitingUniversity of Colorado, Denver102024-02-082026-08-25
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
AzaCITIDine Oral Tablet, Xospata - AML, Adult, Refractory AML
Phase 2RecruitingFrench Innovative Leukemia Organisation332024-01-132025-03-24
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
oral azacitidine (CC-486) - Acute Myeloid Leukemia
Phase 2WithdrawnYale University2023-11-012023-12-26
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Azacitidine, Biopsy, Enasidenib - Acute Myeloid Leukemia
Phase 2RecruitingAlice Mims1252022-09-132026-06-23
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
CC-486, Placebo - Leukemia, Myeloid, Acute
Phase 2Active not recruitingBristol-Myers Squibb342022-08-192026-04-28
Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
Azacitidine, Quality-of-Life Assessment, Questionnaire Administration - Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
Phase 2Active not recruitingUma Borate332022-06-232026-05-14
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
Azacitidine, Decitabine, Venetoclax - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Phase 2RecruitingBrian Jonas202022-02-092024-05-29
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Oral Azacitidine, Placebo - Acute Myeloid Leukemia
Phase 2Active not recruitingBristol-Myers Squibb192022-01-172026-02-11
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Azacitidine, Seclidemstat - Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center242021-07-072026-09-18
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
Magrolimab, Azacitidine, Venetoclax - Myeloid Malignancies
Phase 2TerminatedGilead Sciences542021-06-282025-03-20
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma
Phase 2 / Phase 3Active not recruitingNational Cancer Institute (NCI)4222021-05-202026-11-12
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center172021-03-252025-05-23
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Azacitidine, Magrolimab, Venetoclax - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center1102020-07-282026-04-23
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
Azacitidine, Venetoclax - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia
Phase 2Active not recruitingM.D. Anderson Cancer Center1002020-05-052026-10-05
Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement
Azacitidine, Pinometostat - Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL, Leukemia Cutis
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)12020-03-062023-10-18
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Azacitidine, Gilteritinib, Venetoclax - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
Phase 1 / Phase 2RecruitingM.D. Anderson Cancer Center972019-12-172026-10-06
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
Azacitidine, Venetoclax - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center512019-10-012026-02-12

Showing 20 of 26. Sign in to see all of them.

Conditions studied

Leukemia, Myeloid, Acute (19)  ·  Myelodysplastic Syndromes (6)  ·  Leukemia, Myelomonocytic, Chronic (5)  ·  Hematologic Neoplasms (3)  ·  Myeloproliferative Disorders (2)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Hematologic Diseases (1)  ·  Hypereosinophilic Syndrome (1)  ·  Leukemia (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Leukemia, Erythroblastic, Acute (1)  ·  Leukemia, Megakaryoblastic, Acute (1)  ·  Leukemia, Monocytic, Acute (1)  ·  Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1)  ·  Leukemia, Myelomonocytic, Acute (1)

Sponsors

M.D. Anderson Cancer Center (10)  ·  National Cancer Institute (NCI) (4)  ·  Bristol-Myers Squibb (2)  ·  Alice Mims (1)  ·  Brian Jonas (1)  ·  Celgene (1)  ·  Eastern Cooperative Oncology Group (1)  ·  French Innovative Leukemia Organisation (1)  ·  Gilead Sciences (1)  ·  Jacqueline Garcia, MD (1)  ·  Uma Borate (1)  ·  University of Colorado, Denver (1)  ·  Yale University (1)

Countries

United States (22)  ·  United Kingdom (2)  ·  Australia (1)  ·  China (1)  ·  France (1)  ·  Japan (1)

Top investigators

Brian A Jonas (2)  ·  Nicholas Short (2)  ·  Alice S Mims, MD (1)  ·  Betul Oran (1)  ·  Christine McMahon, MD (1)  ·  Courtney DiNardo, MD (1)  ·  Ehab Atallah, MD (1)  ·  Elizabeth A Brem (1)  ·  Guillermo Garcia-Manero (1)  ·  Guillermo M Bravo (1)  ·  Jacqueline Garcia, MD (1)  ·  Kamal Menghrajani (1)  ·  Lohith Gowda, MD (1)

Results publications

PMID 31212080, PMID 34686472, PMID 34889407, PMID 35704787, PMID 36063832, PMID 36841758, PMID 37422688, PMID 38277619, PMID 40073835, PMID 40364806, PMID 40513054, PMID 42035228, PMID 42200455

NIH funding

2023 (1), P30CA093373 (1), R01CA262496 (1), T32CA233414 (1), U10CA031946 (1), U10CA180821 (1), U10CA180888 (1), UM1CA186691 (1), UM1CA186717 (1)